PCSK9 and metabolic syndrome: A proportion of patients with dyslipidemia, such as those with familial hypercholesterolemia, are not responsive to drugs commonly used to treat dyslipidemia, such as high-dose statins, ezetimibe, or PCSK9 inhibitors.